EC Number |
Inhibitors |
Structure |
---|
2.3.1.61 | 2-(2,4-dichloro-3-[[(prop-2-yn-1-yl)oxy]methyl]phenyl)-5-(ethanesulfonyl)-1,3,4-oxadiazole |
- |
|
2.3.1.61 | 2-(2,4-dichloro-3-[[(prop-2-yn-1-yl)oxy]methyl]phenyl)-5-(methanesulfonyl)-1,3,4-oxadiazole |
- |
|
2.3.1.61 | 2-(4-fluoro-3-[[(prop-2-yn-1-yl)oxy]methyl]phenyl)-5-(methanesulfonyl)-1,3,4-oxadiazole |
- |
|
2.3.1.61 | 2-(4-fluorophenyl)-5-(methanesulfonyl)-1,3,4-oxadiazole |
- |
|
2.3.1.61 | 2-(ethanesulfonyl)-5-(4-fluoro-3-[[(prop-2-yn-1-yl)oxy]methyl]phenyl)-1,3,4-oxadiazole |
- |
|
2.3.1.61 | 2-(ethanesulfonyl)-5-(4-[[(prop-2-yn-1-yl)oxy]methyl]phenyl)-1,3,4-oxadiazole |
- |
|
2.3.1.61 | 2-(methanesulfonyl)-5-(4-[[(prop-2-yn-1-yl)oxy]methyl]phenyl)-1,3,4-oxadiazole |
- |
|
2.3.1.61 | 2-(methylsulfonyl)-5-(4-fluoro-3-((prop-2-yn-1-yloxy)methyl)-phenyl)-1,3,4-oxadiazole |
- |
|
2.3.1.61 | coenzyme Q0 |
formation of coenzyme Q0-dihydrolipoamide adducts in the E2 components of the alpha-ketoglutarate complex (i.e. dihydrolipoamide succinyltransferase) partially explains the cellular toxicity of coenzyme Q0 |
|
2.3.1.61 | more |
no activity with 5-(4-fluoro-3-((prop-2-yn-1-yloxy)methyl)phenyl)-1,3,4-oxadiazol-2-ol |
|